November 18, 2022Open Access

AlphaBet: Combination of Radium-223 and 177LuLu-PSMA-I&T in men with metastatic castration-resistant prostate cancer (clinical trial protocol)

LKLouise KostosThe University of Melbourne JBJames P ButeauThe University of Melbourne TYTheresa YeungPeter MacCallum Cancer Centre

Key Points

Key points are not available for this paper at this time.

Abstract

Background: Lu]Lu-PSMA will improve eradication of micrometastatic osseous disease, and thereby lead to higher and longer responses. Methods: Lu]Lu-PSMA-I&T and the 50% PSA response rate. Conclusion: Lu]Lu-PSMA-I&T in patients with mCRPC. We aim to enroll the first patient in Q3 2022, and recruitment is anticipated to continue for 24 months. Study registration: NCT05383079.

Demander à l'IA

Bookmark

View Full Paper

Cite This Study

Kostos et al. (Fri,) studied this question.

synapsesocial.com/papers/69fd31f47f24f003e82705d4 https://doi.org/https://doi.org/10.3389/fmed.2022.1059122

Demander à l'IA

Bookmark

View Full Paper